RxDoctor Payments DataLook up a doctor →

Roxanne Achong-Coan, OD

Corneal and Contact Management · Ocoee, FLNPI 1366463275

Payments from drug & device makers

$305,573in general payments, 2019–2025

Across 529 payments — averaging $577.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$292K
  • Topcon Healthcare, Inc.$4K
  • Bausch & Lomb Americas Inc.$1K
  • Alcon$1K
  • Notal Vision, Inc.$960
  • Johnson & Johnson Vision Care, Inc.$884
  • plus $5K from 21 others
$77,173in research payments, 2019–2025

Across 3 payments — averaging $25,724 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Coopervision Inc.$77K

What the payments were for

  • Consulting fees$20,04812%
  • Speaking & faculty fees$95,81856%
  • Travel & lodging$40,06923%
  • Food & beverage$15,0399%
  • Entertainment$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$305,573 in reported general payments places this provider in the 95th percentile of 67 corneal and contact management providers in Florida.

See all corneal and contact management providers in Florida

Medicare billing

Part B allowed, 2024
$12,541
Medicare patients
38
Services billed
141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast11$7,646
ValacyclovirValacyclovir Hcl12$426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$1,239$7,64611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 67 corneal and contact management providers in Florida.

Other corneal and contact management in Ocoee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →